Invivo therapeutics announces $9 million registered direct and private placement offerings, priced at-the-market under nasdaq rules

Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market
NVIV Ratings Summary
NVIV Quant Ranking